This invention concerns a method for selecting an inhibitor of a cancer-implicated pathway or of a component of a cancer- implicated pathway for coadministration, with an inhibitor of HSP90, to a subject suffering from a cancer which comprises the following steps: (a) contacting a sample containing cancer cells from a subject with an inhibitor of HSP90 or an analog, homolog or derivative of an inhibitor of HSP90 under conditions such that one or more cancer pathway components present in the sample bind to the HSP90 inhibitor or the analog, homolog or derivative of the HSP90 inhibitor； (b) detecting pathway components bound to the HSP90 inhibitor or to the analog, homolog or derivative of the HSP90 inhibitor； (c) analyzing the pathway components detected in step (b) so as to identify a pathway which includes the components detected in step (b) and additional components of such pathway； and (d) selecting an inhibitor of the pathway or of a pathway component identified in step (c). This invention further concerns a method of treating a cancer patient by coadministering an inhibitor of HSP90 and an inhibitor of a cancer- implicated pathway or component thereof.Esta invención se refiere a un método para seleccionar un inhibidor de una trayectoria implicada con el cáncer, o de un componente de una trayectoria implicada con el cáncer para coadministración, con un inhibidor de Hsp90 a un sujeto que padece de cáncer, que comprende las siguientes etapas: (a) poner en contacto una muestra que contiene células de cáncer de un sujeto con un inhibidor de Hsp90, o el análogo, homólogo o derivado de un inhibidor de HSP90 bajo condiciones tales, que uno o más componentes de la trayectoria del cáncer presentes en la muestra se enlacen a un inhibidor de HSP90, o el análogo, homólogo o derivado del inhibidor HSP90； (b) detectar los componentes de la trayectoria enlazados al inhibidor HSP90 o a un análogo, homólogo o derivado del inhibidor HSP90； (c) analizar los componentes de la traye
